We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+27.7%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$18.4B
AUM Growth
+$1.73B
Cap. Flow
-$958M
Cap. Flow %
-5.21%
Top 10 Hldgs %
90.4%
Holding
118
New
7
Increased
23
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$60.8M
2
SWTX
SpringWorks Therapeutics
SWTX
+$35.8M
3
ROIV icon
Roivant Sciences
ROIV
+$33.4M
4
KYNB
Kyntra Bio
KYNB
+$26.7M
5
BPMC
Blueprint Medicines
BPMC
+$15M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$605M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$395M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$110M
4
TVTX icon
Travere Therapeutics
TVTX
+$25.8M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$9.5B 51.68%
46,913,769
+1,503
+0% +$241K
INCY icon
2
Incyte
INCY
$25.5B
$2.61B 14.22%
36,175,400
+20,429
+0.1% +$1.6M
ONC
3
BeOne Medicines Ltd
ONC
$34.2B
$2.51B 13.68%
11,668,897
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.53B
$789M 4.29%
41,938,486
+15,000
+0% +$286K
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$12.6B
$374M 2.04%
1,545,113
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.9B
$371M 2.02%
3,810,248
-3,810,246
-50% -$395M
IMCR icon
7
Immunocore
IMCR
$1.71B
$125M 0.68%
2,520,731
– –
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.42B
$116M 0.63%
6,498,267
+143,659
+2% +$3.61M
KOD icon
9
Kodiak Sciences
KOD
$2.59B
$107M 0.58%
17,310,490
– –
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.47B
$106M 0.58%
12,710,818
– –
ARGX icon
11
argenx
ARGX
$55.3B
$104M 0.57%
280,159
– –
AKRO
12
DELISTED
Akero Therapeutics
AKRO
$90.6M 0.49%
2,368,378
– –
KYMR icon
13
Kymera Therapeutics
KYMR
$8.88B
$85.3M 0.46%
2,879,825
– –
REPL icon
14
Replimune Group
REPL
$464M
$80.9M 0.44%
4,578,280
– –
ABCL icon
15
AbCellera Biologics
ABCL
$1.69B
$78.8M 0.43%
10,450,180
– –
SWTX
16
DELISTED
SpringWorks Therapeutics
SWTX
$70.9M 0.39%
2,753,502
+1,224,964
+80% +$35.8M
TRDA icon
17
Entrada Therapeutics
TRDA
$260M
$70.6M 0.38%
4,865,819
– –
BMEA icon
18
Biomea Fusion
BMEA
$91.1M
$65.4M 0.36%
2,108,949
+4,390
+0.2% +$54.6K
RVMD icon
19
Revolution Medicines
RVMD
$39.1B
$58.3M 0.32%
2,691,493
+2,469,271
+1,111% +$60.8M
PRLD icon
20
Prelude Therapeutics
PRLD
$385M
$57.7M 0.31%
10,123,824
– –
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$52.4M 0.29%
1,409,784
– –
KYNB
22
Kyntra Bio
KYNB
$27.9M
$49.2M 0.27%
105,495
+50,487
+92% +$26.7M
CERS icon
23
Cerus
CERS
$585M
$47.7M 0.26%
16,067,558
– –
IGMS
24
DELISTED
IGM Biosciences
IGMS
$43.4M 0.24%
3,156,656
+554
+0% +$11.5K
JBIO
25
Jade Biosciences
JBIO
$1.22B
$39.6M 0.22%
56,099
-383
-0.7% -$318K
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Baker Bros. Advisors held 118 positions worth $18.4B, up 10% from $16.7B the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Baker Bros. Advisors withdrew a net $958M in Q1 2023, closing 13 positions and reducing 7 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $605M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Blueprint Medicines worth $15M.

  • Baker Bros. Advisors's largest Q1 2023 buy was Blueprint Medicines: 333,665 shares worth $15M.
  • Baker Bros. Advisors added most to Revolution Medicines in Q1 2023, an estimated $60.8M increase.
  • Baker Bros. Advisors's biggest Q1 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $395M.
  • Baker Bros. Advisors fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $605M.
  • Baker Bros. Advisors's ten largest holdings make up 90% of its $18.4B portfolio in Q1 2023.
  • Baker Bros. Advisors opened 7 new positions and closed 13 in Q1 2023.
  • Baker Bros. Advisors's portfolio value rose 10% quarter-over-quarter to $18.4B.

Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.